Alcon has launched its Voyager DSLT (Direct Selective Laser Trabeculoplasty device), the first and only device of its kind, in the U.S.

Voyager DSLT delivers 120 laser pulses without needing a gonio lens as with a manual DSLT, according to the company. SLT is recognized as an effective first-line therapy but its duration of treatment and specialized training necessary for a manual SLT have limited its accessibility.

Voyager DSLT is controlled through a touchscreen, which removes the slit lamp and manual gonio lens aiming from the equation. It also reduces the specialized training needed for a manual SLT.

Precise delivery is enabled by Alcon’s SureTrac eye-tracking tech to accurately and safely deliver laser pulses through the limbus to the trabecular network. This stimulates the eye’s natural healing response to improve aqueous outflow, the company said.

Further, 96% of surgeons in a 24-subject study who experienced a DSLT demo agreed they would like to be offered first-line DSLT if they were patients.

A trial showed DSLT delivers effective intraocular pressure (IOP) control with a strong safety profile and low adverse event risk. 62% of participants were medication-free at 12 months and after six months, almost all DSLT patients said they would recommend the treatment to a friend with glaucoma.

“I have been using Voyager DSLT since October of 2024, and it has made an incredible impact on the use of SLT for my practice,” said Inder Paul Singh, MD, President of The Eye Centers of Racine and Kenosha. “My patients have been delighted by the efficiency, comfort level of the treatment, and overall experience. Voyager DSLT has been embraced by my staff and is easy to implement, allowing me to treat more of my patients with a recognized first-line standard in glaucoma treatment.”

“Alcon is dedicated to developing treatments and technologies for people living with glaucoma,” added Terry Kim, MD, chief medical officer and Head of Global Medical Safety, Alcon. “By introducing Voyager DSLT, we’re able to broaden access to first-line SLT therapy and provide Eye Care Professionals with crucial early intervention for their glaucoma patients.”

In December 2024, the company launched its PRECISION7 line of contact lenses in the U.S. The one-week replacement lens has a seven-day ACTIV-FLO system, which offers 16 hours of comfort and precise vision even on day seven.